CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
piggyBac 转座子介导的 CAR-T 细胞用于血液系统与实体恶性肿瘤治疗
英文原题：piggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies.
查看英文原题
piggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自CAR-T 细胞疗法（CAR-T 疗法）问世并显著改变B细胞肿瘤的治疗策略以来，各种CAR-T 细胞产品已被开发，并拓展应用于髓系和实体瘤。尽管病毒载体已广泛用于制备基因工程化T细胞，基因工程技术进步也推动了非病毒基因修饰CAR-T 细胞制备方法的发展。近期进展显示，非病毒CAR-T 不仅显著简化制备流程、提高非病毒载体的可及性，也会影响细胞本身的功能。本综述聚焦非病毒基因修饰CAR-T 细胞中的piggyBac转座子系统CAR-T 细胞，讨论其特征、临床前开发和近期临床应用。
展开英文摘要原文
Since the introduction of the use of chimeric antigen receptor T-cell therapy (CAR-T therapy) dramatically changed the therapeutic strategy for B cell tumors, various CAR-T cell products have been developed and applied to myeloid and solid tumors. Although viral vectors have been widely used to produce genetically engineered T cells, advances in genetic engineering have led to the development of methods for producing non-viral, gene-modified CAR-T cells.
Recent progress has revealed that non-viral CAR-T cells have a significant impact not only on the simplicity of the production process and the accessibility of non-viral vectors but also on the function of the cells themselves. In this review, we focus on piggyBac-transposon-based CAR-T cells among non-viral, gene-modified CAR-T cells and discuss their characteristics, preclinical development, and recent clinical applications.
论文信息
- 作者
- Yagyu S、Nakazawa Y
- 单位
- Innovative Research and Liaison Organization, Shinshu University, 3-1-1, Asahi, Matsumoto, Nagano, Japan. shigeky@shinshu-u.ac.jp.Japan
- 文献类型
- 综述
- 期刊
- International journal of clinical oncology2023 Jun
- 原文标识
- PubMed 36859566 · DOI 10.1007/s10147-023-02319-9